Hyderabad-based health-tech company Litemed India has introduced Curapod M, a drug-free, hormone-free device designed to help manage menstrual pain and cramps using photobiomodulation (PBM) technology.
Developed and manufactured in India, Curapod M combines medical-grade PBM with adaptive personalisation and digital technology. The company said the device is licensed by the Central Drugs Standard Control Organisation (CDSCO) and registered with the US Food and Drug Administration (FDA).
At the centre of Curapod M is a clinically validated photobiomodulation platform designed to target biological processes associated with menstrual pain, including prostaglandin-linked pathways involved in cramping.
In a clinical evaluation cited by the company, 80% of women reported zero pain after using Curapod M. The device is designed for use around the lower abdomen, allowing users to incorporate the therapy into their daily routines.
“Menstrual pain is driven by real biological processes. With Curapod M, the intent was to go beyond simply responding to the sensation of pain and build technology that works further upstream on the mechanisms associated with it. That is where photobiomodulation and adaptive personalisation come together,” saidSurya Prakash, founder and chief technology officer, CURAPOD.
Curapod M uses specific red and near-infrared wavelengths through photobiomodulation, supported by a proprietary adaptive engine that personalises therapy. Its companion app uses information on the user’s menstrual cycle, pain patterns and therapy history to anticipate the likely intensity of an upcoming cycle.
“For generations, women have learned to organise parts of their lives around menstrual pain. We believe the next generation should inherit something different. Curapod M is our attempt to change that expectation through science and technology,”said Sri Velliyur, co-founder and CEO, CURAPOD.
Curapod M to roll out across India
Curapod M is expected to be available in India through the Curapod website, Amazon and Flipkart, with an indicative launch price of around Rs 11,999. The company plans to make the product available across metropolitan and Tier 2 markets.
The launch builds on Curapod’s existing pain- technology platform, which the company said has been used across more than 50,000 Indian households and for more than one million therapy sessions.
“India has the science and engineering capability to build healthcare innovation for the world. But invention alone does not create impact. Awareness, trust, adoption and distribution determine whether great science actually reaches people. Curapod M gives us an opportunity to build not only an India-made technology, but an India-led women’s health category with global relevance,”said Aditi Wadhwa, chief marketing officer, CURAPOD.
Menstrual pain in India
The launch comes against the backdrop of the reported prevalence of menstrual pain among adolescent girls and women in India. A 2025 meta-analysis of 31 studies across India estimated that 53% of adolescent girls aged 10–19 experience menstrual pain, with individual studies reporting prevalence ranging from 26.3% to 84.2%, depending on the population and methodology.
Menstrual pain can have an impact beyond physical discomfort, affecting education, work, productivity and overall quality of life.
According to the data cited by the company, girls experiencing menstrual pain were 4.9 times more likely to miss college.
Furthermore, research has found a 3.2 times higher likelihood of reduced concentration and a 2.4 times higher likelihood of poor work satisfaction among women experiencing menstrual pain.
A 2023 review cited by the company reported that nearly 48% of women experienced sickness absenteeism associated with menstrual pain.
